Financiere des Professionnels Fonds d investissement inc. Takes Position in United Therapeutics Corporation $UTHR

Financiere des Professionnels Fonds d investissement inc. purchased a new position in United Therapeutics Corporation (NASDAQ:UTHR) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 1,849 shares of the biotechnology company’s stock, valued at approximately $1,096,000.

Other hedge funds also recently bought and sold shares of the company. Sage Rhino Capital LLC lifted its holdings in United Therapeutics by 5.1% in the first quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock valued at $281,000 after acquiring an additional 23 shares during the period. Bryn Mawr Trust Advisors LLC grew its stake in shares of United Therapeutics by 5.4% during the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock valued at $276,000 after purchasing an additional 24 shares during the period. Independent Advisor Alliance grew its stake in shares of United Therapeutics by 3.3% during the 4th quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock valued at $406,000 after purchasing an additional 27 shares during the period. Florida Financial Advisors LLC increased its position in shares of United Therapeutics by 5.4% during the 4th quarter. Florida Financial Advisors LLC now owns 550 shares of the biotechnology company’s stock valued at $268,000 after purchasing an additional 28 shares during the last quarter. Finally, NDVR Inc. increased its position in shares of United Therapeutics by 5.1% during the 4th quarter. NDVR Inc. now owns 616 shares of the biotechnology company’s stock valued at $300,000 after purchasing an additional 30 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Up 1.3%

NASDAQ UTHR opened at $535.67 on Friday. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35. The company has a market capitalization of $22.74 billion, a P/E ratio of 19.77, a price-to-earnings-growth ratio of 1.77 and a beta of 0.58. The stock’s 50-day moving average price is $552.38 and its 200-day moving average price is $530.14.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company’s revenue was down 1.6% compared to the same quarter last year. During the same quarter last year, the firm posted $6.63 earnings per share. Research analysts anticipate that United Therapeutics Corporation will post 26.63 EPS for the current year.

Insiders Place Their Bets

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $572.61, for a total value of $5,726,100.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at $10,808,586.36. This represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold a total of 564,743 shares of company stock worth $316,423,257 over the last quarter. 8.60% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Royal Bank Of Canada raised their price objective on shares of United Therapeutics from $701.00 to $704.00 and gave the stock an “outperform” rating in a report on Tuesday, July 7th. HC Wainwright upped their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a report on Tuesday, March 31st. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Finally, Morgan Stanley set a $516.00 price objective on shares of United Therapeutics in a research report on Thursday, May 7th. Ten investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $644.82.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.